Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Article from sickeconomics:

July 20, 2019. Marker Therapeutics (MRKR). Phase 1/2 Trial Presentation, Pancreatic Cancer.
On July 20, 2019 Marker’s investigators from Baylor College of Medicine will deliver a presentation at the upcoming American Association for Cancer Research’s (AACR) conference. Thus far Marker is touting impressive results in hematological cancers with its multi-antigen, tumor-specific T-cell therapies (MultiTAA). This presentation will give us a first peek at Marker’s progress in pancreatic cancer where new treatment options continue to be desperately needed. Marker’s technology promises to be a simpler, cheaper alternative to the highly publicized, but extremely complicated and costly CAR-T therapies.

https://www.sickeconomics.com/2019/07/12/smallcap-biotechs-catalysts-fda-approval/